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INTRODUCTION
In deoxycorticosterone acetate (DOCA)-salt hypertensive
rats the development and maintenance of hypertension is
considered to be independent of the renin-angiotensin system,
because plasma renin in this model is low (1), and peripher-
al administration of angiotensin converting enzyme (ACE)
inhibitors (2) or angiotensin (Ang) II receptor antagonists
(3) has no effect on blood pressure (BP). However, there is
some evidence for a role of the brain renin-angiotensin sys-
tem in the pathogenesis of DOCA-salt hypertension in rats.
DOCA-salt-treated rats show higher Ang II receptor den-
sity in brain areas involved in cardiovascular regulation, such
as the nucleus of solitary tract, area postrema, median pre-
optic nucleus, subfornical organ, and solitary vagal area (4-
6), and have elevated levels of renin and Ang II in hypotha-
lamus and brain stem nuclei (7, 8). Acute intracere-
broventricular (icv) administration of captopril decreases the
blood pressure of DOCA-salt hypertensive rats (9). Chronic
icv administration of captopril attenuates the development
of hypertension in DOCA-salt hypertensive rats (10). How-
ever, the interpretation of these findings is complicated
because ACE is involved in the metabolism of various pep-
tides that may participate in regulating BP, including
bradykinin, enkephalin and substance P (11).
Three studies assessed the effects of icv Ang II receptor
antagonists on BP in DOCA-salt hypertensive rats. Acute icv
administration of salarasin did not lower BP during 30 min
of follow-up (12). In contrast, injection of losartan icv or into
the rostral part of the third ventricle did lower BP for more
than 1 hr in 4 weeks DOCA-salt hypertensive rats (13).
Moreover, continuous icv infusion of CV-11974 (active
metabolite of candesartan) for 7 days lowered BP from the
fourth day after infusion (14). However, because hemodynam-
ic measurements in these studies were done under anesthesia
in 4 weeks and 6 weeks DOCA-salt hypertensive rats, the role
of brain Ang II in the development of the hypertension in the
DOCA-salt hypertensive rat model is not known yet.
The aim of the present study was to determine the acute
central effects of the type 1 Ang II (AT1) receptor antagonist
losartan in conscious DOCA-salt hypertensive rats, at either
2 weeks during the development of the hypertension or at 4
weeks in the maintenance phase of the hypertension.
MATERIALS AND METHODS
Animals 
Male Wistar rats aged 5 weeks, weighing 140-170 g, were
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Effects of Centrally Administered Losartan on Deoxycorticosterone-
salt Hypertension Rats
To investigate whether brain AT1 receptor stimulation contributes as a hyperten-
sive mechanism to deoxycorticosterone acetate (DOCA)-salt hypertension, losar-
tan (1 mg/4 L) or artificial cerebrospinal fluid (aCSF) was injected into the lateral
cerebral ventricle in conscious control uninephrectomized Wistar rats or rats with
DOCA-salt for 2 or 4 weeks, and mean arterial pressure (MAP) and heart rates
(HR) were recorded. In rats with DOCA-salt treatment, resting MAP increased to
144±6 mmHg after 2 weeks and to 170±5 mmHg after 4 weeks versus 115-
120 mmHg in controls. In rats with 2 week DOCA-salt treatment, MAP started
declining at 4 hr after intracerebroventricular (icv) injection of losartan, and signifi-
cant decreases in MAP were found at 18 and 24 hr. In rats with 4 week DOCA-
salt treatment, MAP was significantly decreased at 4, 18 and 24 hr. In both groups
MAP decreased to that of control rats. In control rats, icv losartan had no effect
on MAP and HR. Icv aCSF did not significantly change MAP and HR in either
DOCA-salt hypertensive rats or control rats. Normalization of MAP after icv admin-
istration of the AT1 receptor antagonist suggests a significant role for brain AT1
receptor stimulation in the development and maintenance of hypertension in the
DOCA-salt hypertensive rat model.
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purchased from Charles River, Montreal, Canada and housed
two per cage at 24℃on a 12 hr light/dark cycle, and allowed
normal rat chow and tap water ad libitum for at least 5 days
prior to entering the study.  All experimental procedures were
approved and carried out in accordance with the guidelines of
the University of Ottawa Animal Care Committee for the use
and care of laboratory animals.
DOCA-salt hypertension
After 5-7 days of acclimatization, under halothane anes-
thesia, all rats underwent a left nephrectomy. After surgery
they were randomized to either the control or DOCA-salt
group. At twenty-four hours after surgery, rats in the
DOCA-salt group received the first injection of DOCA (25
mg/kg subcutaneously in 0.1 mL sesame oil/100 g body
weight) and 1% NaCl as drinking water. Rats in the con-
trol group (Control) received sesame oil only and distilled
water as drinking water. Treatments continued at 3 times a
week for 2 or 4 weeks in two separate experiments. For the
2-week treatment experiment, the following groups were
studied: Control+icv aCSF (n=6); Control+icv losartan (n=9);
DOCA+icv aCSF (n=7); DOCA+icv losartan (n=8), and
for 4 week treatment: Control+icv aCSF (n=7); Control+icv
losartan (n=6); DOCA+icv aCSF (n=6); DOCA+icv losar-
tan (n=8).
Intracerebroventricular cannulation
Intracerebroventricular cannulation was done at least 1
week before arterial cannulation. A guide cannula (23
gauge, stainless steel tubing) was implanted just above the
left lateral cerebroventricle and fixed on the skull of the rat.
The cannula was located 0.5-mm posterior and 1.4-mm lat-
eral to the bregma, and its lower end about 0.3 mm above
the ventricle as previously described (15).
Direct blood pressure measurement and icv injection
About 2 or 4 weeks after nephrectomy, in the early morn-
ing under halothane anesthesia, the right carotid artery was
cannulated with PE-50 polyethylene tubing filled with
heparinized saline. After recovery from the anesthesia for 4-
5 hr, in the afternoon the intra-arterial catheter was con-
nected to a pressure transducer for recording mean arterial
pressure (MAP) and heart rate (HR). The output signals of
the transducer were amplified and fed to an IBM-compati-
ble computer with a data acquisition program (Dataquest
Labpro; Data Science International, St. Paul, MN, U.S.A.)
that allowed on-line analysis of the pulsatile blood pressure
signal and storage of data.
For icv injection, a 26-gauge stainless cannula was insert-
ed into the guide cannula so that its tip protruded 0.8-1.0
mm into the lateral ventricle. A 20- L volume Hamilton
microsyringe was used for icv injections. Injections consist-
ed of a volume of 4- L delivered manually over a period of
2 min (losartan 1 mg dissolved in aCSF, or aCSF). Each rat
received only a single injection.
The resting BP and HR were taken at baseline, and at 1,
2, 4, 18, and 24 hr after icv injection. The accuracy of the
icv cannulation was checked at autopsy with an icv injection
of methylene blue.
All data are expressed as means±SEM. One-way ANOVA
was used to analyze MAP and HR responses to icv losartan,
followed by a Newman-Keuls’ to compare individual read-
ings to the baseline. Values of p<0.05 were considered sta-
tistically significant.
RESULTS
After 2 and 4 weeks of treatment, resting mean arterial
pressure (MAP) increased significantly in rats with DOCA-
salt hypertension versus control rats (144±6 mmHg versus
118±5 mmHg and 170±5 mmHg versus 115±3 mmHg,
p<0.01 for both). No significant difference in resting basal
HR was detected between the two groups. Body weight in
DOCA-salt hypertensive rats was similar to that in controls
after 2 weeks, but was significantly less after 4 weeks (Table 1).
In rats with DOCA-salt for 2 weeks, MAP did not show a
significant change at 1 and 2 hr after icv injection of losartan,
but started declining at 4 hr, and significant decreases in MAP
were found at 18 and 24 hr after icv losartan. In 4 weeks
DOCA-salt hypertensive rats, MAP decreased significantly
at 4, 18 and 24 hr. BP reached that of control rats at 18 and
24 hr at both 2 and 4 weeks (Fig. 1). There was no significant
change of HR (Fig. 2).
In control rats, icv losartan had no effect on BP and HR.
Icv aCSF did not significantly change MAP and HR in either
DOCA-salt hypertensive or control rats (Fig. 1).
Values are expressed as mean±SEM. *p<0.05 and 
� p<0.01 when
compared to the control group treated with icv aCSF or losartan. BW,
body weight. MAP, mean arterial pressure. HR, heart rate. DOCA,
deoxycorticosterone acetate. bpm, beats per minute
MAP (mmHg) HR (bpm) BW (g)
Two weeks
Control aCSF (n=6) 110±5 387±13 301±12
Losartan (n=9) 122±6 415±7 302±10
DOCA-salt aCSF (n=7) 142±8* 392±16 303±8
Losartan (n=8) 146±9* 418±18 284±8
Four weeks
Control aCSF (n=7) 115±3 383±8 342±9
Losartan (n=7) 115±3 390±16 357±9
DOCA-salt aCSF (n=6) 163±8
� 403±4 301±12*
Losartan (n=8) 174±7
� 405±20 289±6*
Table 1. Resting mean arterial pressure, heart rate and body
weight in rats 2 or 4 weeks on DOCA-saltCentral Losartan and DOCA-salt Hypertension 555
DISCUSSION
The brain renin-angiotensin system (RAS) contributes to
the development and maintenance of certain forms of salt-
sensitive hypertension. Chronic blockade of brain AT1 recep-
tors by icv losartan prevents both the sympathetic hyper-
activity and exacerbation of hypertension in SHR on high
sodium (15). Chronic icv infusion of the AT1 receptor
blocker CV-11974 (active metabolite of candesartan) or
losartan prevents the development of hypertension in Dahl-
Iwai salt-sensitive rats (16) and Dahl S rats (17). Therefore,
activation of brain AT1 receptors seems to be essential for
development of salt-sensitive hypertension in SHR and
Dahl S rats.
In unilaterally nephrectomized rats, blood pressure rises
between 1-2 weeks after start of DOCA-salt treatment (18-
23). After 4 weeks, blood pressure has further increased and
remains elevated even after stopping steroid treatment (post-
DOCA-salt hypertension) (24). Depending on the dose of
steroid and sodium intake, rats with systolic blood pressure
in excess of 200 mmHg enter a malignant phase and die
with brain, vascular and renal lesions with weight loss. In
the present study, 1 among 15 rats after 2 weeks and 11
among 14 rats after 4 weeks of DOCA-salt treatment had
systolic blood pressure over 200 mmHg. We used 2-week
rats to assess the role of Ang II in the development of DOCA-
salt hypertension and 4-week rats to evaluate the role of
Ang II in the maintenance of DOCA-salt hypertension.
From a biochemical point of view, there is evidence for
increased activity of the brain RAS during the development
of DOCA-salt hypertension. After DOCA-salt treatment
for 1 month, renin-like activity and Ang II in hypothala-
mus and brain stem nuclei were elevated, but plasma renin
activity was very low (7, 8). In rats with DOCA-salt hyper-
tension for 4-8 weeks, angiotensin II receptor binding on
autoradiography was also elevated in selected brain areas
involved in cardiovascular regulation, such as nucleus of
solitary tract, area postrema, median preoptic nucleus, sub-
fornical organ, and solitary vagal area (4-6). Moreover, BP
responses to centrally administered Ang II were significant-
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Fig. 1. Time course of changes in mean arterial pressure (MAP)
after injection of losartan 1 mg/4 L or artificial CSF into the later-
al ventricle of the brain. Values represent mean±SEM. Asterisks
below the line designate difference from basal in DOCA+losar-
tan group. *p<0.05, **p<0.01.
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Fig. 2. Time course of changes in heart rate (HR) after injection
of losartan 1 mg/4 L or artificial CSF into the lateral ventricle of
the brain. Values represent mean±SEM. bpm, beats per minute.
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ly augmented after 3 and 8-10 weeks of DOCA-salt treat-
ment in rats (4, 25).
However, acute icv infusion of the Ang II antagonist sar-
alasin led to a significant dose-dependent increase in BP 30
min after infusion in DOCA-salt hypertensive rats (12).
This pressor response might be due to partial agonist activi-
ty of saralasin (26) in conjunction with increased number
and sensitivity of brain Ang II receptors. Since nonpeptide
AT1 receptor blockers such as losartan lack agonist activity,
they may be used to specifically examine the functional role
of AT1receptors. In the present study, after 2 weeks of DOCA-
salt treatment losartan decreased the MAP to control levels
at 18 and 24 hr after the injection. The decrease in BP
developed slowly and did not occur until 4 hr postinjection.
These data indicate that brain AT1 receptor stimulation
plays a major role in the development of hypertension in
DOCA-salt rats. Since icv injection of losartan also normal-
ized the MAP once the hypertensive state is established (4
weeks of DOCA-salt), the brain RAS continues to play a
major role in the maintenance of DOCA-salt hypertension.
Injection of losartan into the lateral ventricle or the rostral
parts of the third ventricle decreased BP in 4 weeks DOCA-
salt hypertensive rats by 10-17 mmHg (14). These depressor
responses to losartan began within 1min, reached a plateau
within 20 min and lasted for more than 1 hr (13). In con-
trast, in the current study icv losartan decreased arterial
pressure until 4 hr after injection, and control levels of BP
were reached at 18-24 hr after injection. Others also
observed delayed BP responses to AT1 receptor blockers
after icv administration. Continuous icv infusion of the AT1
receptor blocker CV-11974 for 7 days lowered the BP only
from the fourth day after the start of the infusion in 6 week
DOCA-salt treated rats (14). Pare et al. demonstrated that
in SHR, losartan induced long-lasting (days) BP reductions
(≤40 mmHg), only at 18 hr after icv injection, but not
EXP-3174, an active metabolite of losartan. They hypothe-
sized that the slow development of BP reduction and its
persistence might be due to the formation of an active
metabolite, different from EXP-3174 (27).
Besides Ang II, vasopressin, endothelin (28, 29), and the
sympathoadrenal system may also contribute to the devel-
opment and maintenance of DOCA-salt hypertension in
rats. Central pathways involving AT1 receptor stimulation
may contribute to increases in arginine vasopressin (AVP)
and sympathetic activity, which contribute to the increases
in BP in DOCA-salt rats (25, 40). Acute icv injection of
CV-11974 decreased plasma concentration of AVP, and uri-
nary excretion of AVP decreased from the fourth day of con-
tinuous icv infusion of CV-11974 (14). It is therefore possi-
ble that inhibition of brain AT1 receptor results in a decrease
of AVP release and therefore BP with some latency for as
yet unclear reasons.
In summary, centrally administered losartan normalized
BP in DOCA-salt hypertensive rats. These results support
the concept that the brain RAS and specifically brain AT1
receptor stimulation may contribute to the development and
maintenance of hypertension in this model.
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